Novartis Pregnancy Drug Exposure Registry for Female CML Patients

Novartis Oncology, the manufacturer of Gleevec® & Tasigna® has established this Pregnancy Drug Exposure Registry to learn about pregnancy outcomes and the health of women who have taken Gleevec® and/or Tasigna® within six months prior to conception or during pregnancy. The information gathered in this Registry may supplement other sources of data and assist clinicians and patients in weighing the risks or benefits of being exposed to these medications around conception and during pregnancy.